$SANA Stock Is up 15% Today. Here's What We See in Our Data.
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica, an AI-Powered Drug Discovery Platform
BofA Securities Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $7
Sana Biotechnology Faces Uncertainty as Financial Struggles Threaten Future Operations
TD Cowen Maintains Sana Biotechnology(SANA.US) With Buy Rating
JMP Securities Upgrades Sana Biotechnology(SANA.US) to Buy Rating, Announces Target Price $5
H.C. Wainwright Maintains Sana Biotechnology(SANA.US) With Buy Rating, Maintains Target Price $11
Sana Biotechnology Shares Are Trading Lower. The Company Reported Q4 Financial Results.
Citizens Capital Markets Upgrades Sana Biotechnology to Market Outperform, Announces $5 Price Target
Express News | HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $11 Price Target
Sana Biotechnology Reports 2024 Financial Results and Progress
Sana Biotechnology | 10-K: FY2024 Annual Report
Sana Biotechnology, Inc. Reports Positive 12-Week Clinical Results for Type 1 Diabetes Therapy and Financial Overview for Q4 2024
Express News | Sana Biotechnology Q4 2024 Adj. EPS $(0.23), Inline
Sana Biotechnology | 8-K: Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Express News | Sana Biotechnology Inc - Expects to File Inds for Sc451 and SG299 as Early as 2026
Express News | Sana Biotechnology: Q4 2024 Cash Position of $152.5 Mln and Expected Cash Runway Into 2026
Express News | Sana Biotechnology Q4 Net Income USD -49.069 Million
Press Release: Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates